Evommune, Inc.
- EVMN · NYSE
- Pharmaceutical Preparations
- Palo Alto, CA
- 48 employees
- CIK 0002044725
Updated from SEC filings through
Top things to know
Executives
- Luis C. Pena President & CEO 4, 2026-06-24
- Kyle Carver Chief Financial Officer 4, 2026-07-10
- Janice Suzann Drew Chief of Dev. Operations 4, 2026-06-24
- Jeegar Pravinkumar Patel Chief Scientific Officer 4, 2026-06-24
- Gregory S. Moss Chief Business & Legal Officer 4, 2026-06-01
- Eugene Bauer Chief Medical Officer 4, 2026-04-17
Evommune, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Palo Alto, CA. It trades as EVMN on NYSE. Revenue was $13.0M in the fiscal year ending December 31, 2025, +85.7% from the year before. It reported about 48 employees. Luis C. Pena is President & CEO.
Five-year financials
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $13.0M 10-K, 2026-03-05 | $7.0M 10-K, 2026-03-05 |
| Operating income | -$81.1M 10-K, 2026-03-05 | -$70.0M 10-K, 2026-03-05 |
| SG&A | $20.0M 10-K, 2026-03-05 | $12.8M 10-K, 2026-03-05 |
| Net income | -$68.9M 10-K, 2026-03-05 | -$66.8M 10-K, 2026-03-05 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Luis C. Pena | President & CEO | 4, 2026-06-24 |
| Kyle Carver Chief Financial Officer at Evommune, Inc. | Chief Financial Officer | 4, 2026-07-10 |
| Janice Suzann Drew | Chief of Dev. Operations | 4, 2026-06-24 |
| Jeegar Pravinkumar Patel | Chief Scientific Officer | 4, 2026-06-24 |
| Gregory S. Moss | Chief Business & Legal Officer | 4, 2026-06-01 |
| Eugene Bauer Chief Medical Officer at Evommune, Inc. | Chief Medical Officer | 4, 2026-04-17 |
| Arthur Kirsch | Director | 10-K, 2026-03-05 |
| David E. Cohen | Director | 10-K, 2026-03-05 |
| Derek DiRocco | Director | 10-K, 2026-03-05 |
| Eugene A. Bauer | Director | 10-K, 2026-03-05 |
| Felice Verduyn-van Weegen | Director | 10-K, 2026-03-05 |
| Rob Hopfner | Director | 10-K, 2026-03-05 |
What Evommune, Inc. does
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 36.3 million (as of August 4, 2026) | 10-Q, August 6, 2026 |
|---|---|---|
| Public float | $0 (as of June 30, 2025) | 10-K, March 5, 2026 |
| Latest proxy statement | Meeting April 21, 2026 (filed April 21, 2026) | DEF 14A, April 21, 2026 |
| Auditor | Bdo Usa, P.c (New York, NY) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| July 8, 2026 | Kyle Carver Chief Financial Officer | Buy | 1,000 | $13K | Form 4, July 10, 2026 |
| July 7, 2026 | Arthur S. Kirsch Director | Buy | 10,000 | $133K | Form 4, July 8, 2026 |
| June 22, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | Sale | 1,488 | $33K | Form 4, June 24, 2026 |
| June 22, 2026 | Janice Suzann Drew Chief of Dev. Operations | Sale | 20,000 | $453K | Form 4, June 24, 2026 |
| June 22, 2026 | Luis C. Pena President & CEO | Sale | 7,438 | $169K | Form 4, June 24, 2026 |
| June 2, 2026 | David E. Cohen Director | Sale | 6,056 | $123K | Form 4, June 3, 2026 |
| June 1, 2026 | Jeegar Pravinkumar Patel Chief Scientific Officer | Sale | 16,687 | $379K | Form 4, June 3, 2026 |
| June 1, 2026 | Luis C. Pena President & CEO | Sale | 16,787 | $382K | Form 4, June 3, 2026 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-11-04
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-10-01
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-23
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-15
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-09
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-30
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-29
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-06-02
- Item 5.07 Submission of matters to a vote of security holders
Frequently asked questions about Evommune, Inc.
- What does Evommune, Inc. do?
- In its own words, from Item 1 of its 10-K: "Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions."
- What is Evommune, Inc.'s revenue?
- $13.0M for the fiscal year ending December 31, 2025, from its 10-K filed March 5, 2026.
- Is Evommune, Inc. profitable?
- Evommune, Inc. reported net income of -$68.9M for the fiscal year ending December 31, 2025.
- How many employees does Evommune, Inc. have?
- About 48 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Evommune, Inc.?
- Luis C. Pena, President & CEO, as named in a 4 filed June 24, 2026.
- Who is the CFO of Evommune, Inc.?
- Kyle Carver, Chief Financial Officer, as named in a 4 filed July 10, 2026.
- Where is Evommune, Inc. headquartered?
- Palo Alto, CA.
- What is Evommune, Inc.'s stock ticker?
- EVMN on NYSE.
- What industry is Evommune, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Evommune, Inc.'s website?
- evommune.com. Investor relations: https://ir.evommune.com.
- When does Evommune, Inc. report earnings next?
- December 10, 2026. Source: pg_future_events.
- Is Evommune, Inc. a public company?
- Yes. Evommune, Inc. files with the SEC under CIK 0002044725 and trades as EVMN.
- Who audits Evommune, Inc.?
- Bdo Usa, P.c, New York, NY, as named in its latest annual report (10-K).
- How many shares of Evommune, Inc. are outstanding?
- 36.3 million shares as of August 4, 2026, from its 10-Q filed August 6, 2026.
- What is Evommune, Inc.'s public float?
- $0 as of June 30, 2025, as reported on the cover of its 10-K filed March 5, 2026.
- When is Evommune, Inc.'s annual shareholder meeting?
- April 21, 2026, per its proxy statement (DEF 14A) filed April 21, 2026.
- Have Evommune, Inc. insiders traded stock recently?
- Since November 7, 2025, officers and directors reported 8 open-market sales worth about $2.3M and 5 purchases worth about $45.2M on Forms 4 and 5. The most recent: Kyle Carver (Chief Financial Officer) bought 1,000 shares on July 8, 2026.